

# Sergey Menis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10801921/publications.pdf>

Version: 2024-02-01

37  
papers

5,496  
citations

172457

29  
h-index

361022

35  
g-index

39  
all docs

39  
docs citations

39  
times ranked

4794  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. <i>Biomaterials</i> , 2021, 275, 120868.	11.4	16
2	Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. <i>Immunity</i> , 2020, 53, 548-563.e8.	14.3	149
3	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22920-22931.	7.1	42
4	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. <i>Npj Vaccines</i> , 2020, 5, 72.	6.0	39
5	In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity. <i>Advanced Science</i> , 2020, 7, 1902802.	11.2	30
6	Engineered immunogen binding to alum adjuvant enhances humoral immunity. <i>Nature Medicine</i> , 2020, 26, 430-440.	30.7	172
7	Nanoparticle Vaccines: In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity (Adv.) <i>Tj ETQq1 110.7843 14 rgBT / Dv</i>		
8	Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16473-16478.	7.1	141
9	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. <i>Immunity</i> , 2019, 51, 141-154.e6.	14.3	71
10	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. <i>Molecular Therapy</i> , 2019, 27, 2080-2090.	8.2	58
11	Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. <i>Cell</i> , 2019, 177, 1153-1171.e28.	28.9	293
12	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. <i>Science</i> , 2019, 363, 649-654.	12.6	227
13	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. <i>Immunity</i> , 2018, 48, 133-146.e6.	14.3	274
14	Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. <i>Scientific Reports</i> , 2018, 8, 16527.	3.3	69
15	Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer. <i>Nature Communications</i> , 2018, 9, 3693.	12.8	124
16	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	113
17	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5.	14.3	110
18	Glycoengineering HIV-1 Env creates "supercharged" and "hybrid" glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	4.7	22

#	ARTICLE	IF	CITATIONS
19	Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. <i>Nature Communications</i> , 2017, 8, 14954.	12.8	176
20	Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. <i>Virology</i> , 2017, 505, 193-209.	2.4	36
21	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016, 353, 1557-1560.	12.6	147
22	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11.	28.9	230
23	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016, 166, 1471-1484.e18.	28.9	198
24	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	14.3	335
25	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	6.4	216
26	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015, 11, e1004932.	4.7	141
27	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015, 349, 156-161.	12.6	358
28	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. <i>Nature Communications</i> , 2015, 6, 7479.	12.8	113
29	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	3.2	51
30	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. <i>Science Translational Medicine</i> , 2014, 6, 236ra63.	12.4	160
31	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A25-A26.	1.1	0
32	Investigating Epitope Exposure on Native Trimers. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A35-A35.	1.1	0
33	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. <i>Science</i> , 2013, 340, 711-716.	12.6	680
34	Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 655-663.	8.5	275
35	An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells. <i>PLoS ONE</i> , 2013, 8, e67309.	2.5	4
36	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	27.8	405

#	ARTICLE	IF	CITATIONS
37	A Chimeric HIV-1 Envelope Glycoprotein Trimer with an Embedded Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Domain Induces Enhanced Antibody and T Cell Responses. Journal of Biological Chemistry, 2011, 286, 22250-22261.	3.4	15